Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2001

View Archived Issues

Antitumor activity of new VEGFR2 inhibitor under study at Boehringer Ingelheim

Gilead achieves several key R&D milestones during Q3

Elan highlights Q3 developments

TAP prodrug of duocarmycin derivative shows increased tumor specificity

Rapid anthrax test will be available to U.S. laboratories next week

Alexion acquires rights to immune system targets

FDA issues nonapprovable letter for IntraDose

Early NDA submission planned for Cellegy's testosterone gel

FDA grants orphan drug status for Thymitaq in treatment of HCC

NeoOncoRx to develop and market elsamitrucin

Antiallergic effects of AZG-1743, a new diphenylmethyl piperazine derivative

Pirfenidone may be useful in asthma Rx according to data presented at recent Japanese meeting

Chest 2001: cilomilast reduces sputum neutrophil count in COPD patients

Clinical course of malignant pleural effusions in NSCLC not changed by rhuMAb-VEGF

Adenosine modulation by pentostatin shows beneficial effects in septic mice

Further subgroup analyses of PROWESS data presented at Chest 2001

TNFerade gene therapy + radiation safely shrinks tumors in phase I trial

Phase III trials of RSR-13 in NSCLC under consideration at Allos based on phase II survival data

New analgesic from Vita enters clinical trials

Cancer-related protease inhibitor from Wilex reduces tumor growth and spread at nontoxic doses

Novel compounds from Knoll inhibit monoamine reuptake, bind to 5-HT1A receptors

Recent patent covers BMS's new DPP-IV inhibitors

Carbamic acid-based IP receptor antagonists reportedly useful for bladder disorders, etc.

Aventis prepares beta-carboline inhibitor of IKK which prolongs cardiac graft survival

New series for obesity and sleep disorders disclosed by Actelion

Selective COX-2 inhibitors synthesized by Almirall Prodesfarma

Novel compounds described in recent patent as chemokine IL-8 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...